Forty-year journey of angiogenesis translational research
- PMID: 22190240
- PMCID: PMC8265598
- DOI: 10.1126/scitranslmed.3003149
Forty-year journey of angiogenesis translational research
Abstract
Forty years ago, Judah Folkman predicted that tumor growth is dependent on angiogenesis and that inhibiting this process might be a new strategy for cancer therapy. This hypothesis formed the foundation of a new field of research that represents an excellent example of how a groundbreaking scientific discovery can be translated to yield benefits for patients. Today, antiangiogenic drugs are used to treat human cancers and retinal vascular diseases. Here, we guide readers through 40 years of angiogenesis research and discuss challenges of antiangiogenic therapy.
Conflict of interest statement
Figures


References
-
- Folkman J, Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med 285, 1182–1186 (1971). - PubMed
-
- Ferrara N, Hillan KJ, Gerber HP, Novotny W, Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov 3, 391–400 (2004). - PubMed
-
- Langer R, Brem H, Falterman K, Klein M, Folkman J, Isolations of a cartilage factor that inhibits tumor neovascularization. Science 193, 70–72 (1976). - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources